NCT06854393

Lacripep for Corneal Wound Healing Study

Lacripep, a Novel Investigational Agent, for Corneal Wound Healing and Ocular Surface Homeostasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine · Academic / Other
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).

Detailed description

The purpose of this study is to assess the effect of an eyedrop medication, Lacripep, on wound healing in the cornea (the transparent tissue covering the front of the eye) such as seen after incidental or combat related trauma, or from eye surgeries like Photorefractive keratectomy (PRK). This study will help understand if Lacripep is an effective treatment in ocular surface healing and speeding visual recovery after injury. Participants must be an active-duty service member or a dependent eligible for care at a military treatment facility.

Conditions

• Corneal Epithelial Wound Healing

Interventions

Type	Name	Description
DRUG	0.00025% Lacripep ophthalmic solution and Placebo	Participant will receive Lacripep in one eye and placebo in the other eye at the same time.

Timeline

• Start date: 2025-05-23
• Primary completion: 2027-06-01
• Completion: 2027-09-01
• First posted: 2025-03-03
• Last updated: 2026-03-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study